What is Zacks Research’s Estimate for Exelixis Q4 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Analysts at Zacks Research raised their Q4 2027 earnings estimates for Exelixis in a research note issued to investors on Thursday, September 3rd. Zacks Research analyst Team now expects that the biotechnology company will earn $1.01 per share for the quarter, up from their prior estimate of $1.00. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.19 per share. Zacks Research also issued estimates for Exelixis’ Q2 2028 earnings at $1.00 EPS and FY2028 earnings at $4.21 EPS.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. The firm had revenue of $628.69 million for the quarter, compared to analyst estimates of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the company posted $0.75 earnings per share.

Several other brokerages also recently weighed in on EXEL. Leerink Partners downgraded Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 target price on the stock. in a research note on Thursday, August 6th. Barclays increased their price target on Exelixis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 14th. Truist Financial lowered their price objective on shares of Exelixis from $56.00 to $52.00 and set a “hold” rating on the stock in a research report on Thursday, August 6th. Stifel Nicolaus boosted their price objective on shares of Exelixis from $47.00 to $51.00 and gave the company a “hold” rating in a research note on Thursday, August 6th. Finally, Wells Fargo & Company upped their price objective on shares of Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $50.07.

Exelixis Stock Up 1.0%

EXEL opened at $59.13 on Friday. Exelixis has a 52 week low of $33.76 and a 52 week high of $59.72. The business has a 50 day moving average price of $54.98 and a two-hundred day moving average price of $49.44. The company has a market cap of $14.65 billion, a PE ratio of 18.59, a P/E/G ratio of 1.74 and a beta of 0.42.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Exelixis in the second quarter valued at $1,581,991,000. California State Teachers Retirement System boosted its position in shares of Exelixis by 4,875.6% during the 2nd quarter. California State Teachers Retirement System now owns 14,785,373 shares of the biotechnology company’s stock worth $804,472,000 after purchasing an additional 14,488,217 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Exelixis by 48.8% during the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after purchasing an additional 4,477,029 shares during the period. Invesco Ltd. grew its stake in shares of Exelixis by 1.6% during the 4th quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock worth $265,379,000 after purchasing an additional 94,218 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Exelixis by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock valued at $184,391,000 after purchasing an additional 39,920 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Activity

In other news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the transaction, the director directly owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. This represents a 37.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.60% of the company’s stock.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.